← Back to headlines
Annexon Outlines Q4 BLA Filing for Tanruprubart
Annexon has detailed its plans for a Q4 Biologics License Application (BLA) filing for tanruprubart, additionally incorporating a month 24 dual primary endpoint into its ARCHER II study.
12 Aug, 18:08 — 12 Aug, 18:08
Sources
Showing 1 of 1 sources
